Drugs / RCT2100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06237335 | Feb 2024 → Aug 2026 overdue | cystic fibrosis | ReCode Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-17 | ReCode Therapeutics | Regulatory ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis recodetx.com ↗ |
| 2025-03-25 | ReCode Therapeutics | Regulatory ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis recodetx.com ↗ |
| 2024-09-26 | ReCode Therapeutics | Results ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston recodetx.com ↗
In the studies, RCT2100, an inhaled mRNA-based therapy, successfully restored CFTR function in patient-derived cells in vitro and improved mucociliary clearance, which is critical for improving patient outcomes, in a ferret model of CF lung disease. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RCT2100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237335 ↗ |
| Modality | Messenger RNA (mRNA) | “RCT2100 (CFTR mRNA)” NCT06237335 ↗ |
| Route | Inhaled | “administered via oral inhalation using nebulizer” NCT06237335 ↗ |